Hypertension

An analysis of data from a 50-year prospective study provides insight into the effects of different pregnancy complications on all-cause mortality later in life.

An analysis of more than 800,000 children with more than 3.5 million person-years of follow-up indicate those in the upper range of average BMI had a 26% greater risk of developing hypertension, with each per unit increase in BMI associated with a 4% increase in risk of hypertension.

At ACC 2023, Hoeper provides insight into the key efficacy findings of STELLAR and delves into the safety concerns and generalizability of sotatercept for PAH.

Hear from Deepak Bhatt, MD, MPH, as he discusses how he interprets the results of the HALO trial and offers perspective on the forthcoming research related to baxdrostat.

Results from the phase 3 A DUE study suggest a combination of macitentan and tadalafil nearly doubled reductions in pulmonary vascular resistance in patients with PAH.

Data from the phase 3 STELLAR trial indicate adding sotatercept to background therapy in PAH was associated with statistically significant improvements in 6-minute walk distance and 8 of the trial's 9 secondary endpoints, including time to death or clinical worsening.

At ACC 2023, HCPLive editorial team sat down with Clyde Yancy, MD, to learn more about his perspective on recent and upcoming advances in cardiovascular care. In this interview, Yancy discusses his perspective on the clinical trial data surrounding renal denervation as a treatment for hypertension.

A genome-wide genetic association study using mendelian randomization provides insight into the causal relationships between HDPs and coronary artery disease and ischemic stroke later in life.

A study presented at the International Stroke Conference 2023 suggests the plasma metabolite gluconic acid could serve as a race-specific biomarker for identifying increased risk of hypertension and stroke in Black adults.

The SPRINT MIND trial is providing new evidence related to the effects of intensive blood pressure lowering on cognitive impairment and risk of dementia according to baseline diastolic blood pressure

An analysis of patient data from the REGARDS cohort suggests the increase in relative risk observed with traditional risk factors, such as hypertension and diabetes, on risk of stroke decreases as patients age, but investigators point out this does not diminish the importance of addressing these risk factors.

Comparing MTO scanning against adrenal vein sampling, investigators in the UK found the noninvasive diagnostic option could improve the identification of primary aldosteronism and candidates for adrenalectomy.

A simulation study including both cardiologists and pulmonologists found providers failed to properly diagnose pulmonary hypertension more than 50% of the time.

Ulcerative colitis was considered an independent risk factor, while Crohn’s disease and unclassified inflammatory bowel disease were not.

Data from the nuMoM2b study suggests greater adherence to a Mediterranean diet was associated with reductions of 37%, 28%, and 21% in odds of gestational diabetes, preeclampsia, and any adverse pregnancy outcome, respectively, among a cohort of more than 7000 nulliparous women.

An analysis of data from the Japanese Collaborative Cohort Study for Evaluation of Cancer Risk suggests those with grade 2-3 hypertension could be increasing their risk of cardiovascular death by consuming 2 or more cups of coffee per day.

Data from the BCQR-T1D study, which was funded by the National Institutes of Health, suggest use of the dopamine receptor agonist bromocriptine was associated with improved blood pressure and arterial stiffness after 4 weeks of treatment in youth with type 1 diabetes.

An analysis of data from deliveries occurring at a large, urban medical center in Boston from 2016-2018 suggests more than 10% of women with no history of hypertension developed hypertension within a year after delivery.

A 10,000-person study provides insight into the feasibility and effectiveness of participation an entirely remote hypertension and lipid management program in a diverse health care network.

Phase 2 data from the BrigHTN trial suggest use of 2 mg baxdrostat was associated with significantly and substantially reduced systolic and diastolic blood pressure in patients with treatment-resistant hypertension. In a Q&A, trial investigator Deepak Bhatt, MD, MPH, provides further insight.

A pooled analysis of data from the RADIANCE-HTN TRIO, RADIANCE-HTN SOLO, and RADIANCE II trials provide a comprehensive overview of the potential reductions in blood pressure possible with renal denervation.

Data from the Diuretic Comparison Project suggests chlorthalidone did not provide a reduction in cardiovascular risk or all-cause mortality compared with use of hydrochlorothiazide in older patients with hypertension.

An analysis of nationally representative data from AHA 2022 suggests most older adults in the US with hypertension were not receiving adequate treatment intensification set forth in US and international guidelines.

An analysis comparing prepandemic blood pressure management against blood pressure management during the first months of the COVID-19 pandemic details rising blood pressure and declining blood pressure control coinciding with the implementation of lockdown and stay-at-home orders.

The beneficial effect of intensive BP control on cardiovascular and all-cause mortality was attenuated during 4.5 years of post-trial after SPRINT.